Psychedelics May Relieve Chronic Pain Via Changes in Brain Neuroplasticity
Using psychedelics to treat chronic pain is understudied yet full of potential.
Articles
MDMA for PTSD Showing Promising Outcomes for Patients in MAPS Phase 3 Trials
“In the pharmaceutical drug development community, this is what you dream about.”
Psychedelics and Endurance Sports: Increased Energy and Reduced Fatigue?
One mechanism of action may be similar to taking amphetamines.
Noribogaine is More Effective Than Fluoxetine in Reducing Depressive Symptoms in Rat Model
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
CaaMTech Partners with the National Institutes of Health to Study Synthetic Tryptamines
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
Antidepressant-Like Effect with A Single Dose of Ibogaine and Noribogaine in Rats
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
Stopping Bad LSD Trips with “Off-Switch” Technology
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
Scientists Solve the Crystal Structure of the Freebase of 5-MeO-DALT
Understanding the structure of this synthetic analog of 5-MeO-DMT may help explain the effects of naturally occurring chemical cocktails.
Two New Crystalline Forms of Norpsilocin
New crystalline forms of norpsilocin create new options for developing psychedelic drug formulations.
The Structure and Function of the Serotonin 5-HT2C Receptor
5-HT2C has a role in the psychedelic effect. Understanding it is essential for harnessing the full benefits of nature’s chemical cocktails.